Limited Neutralization of Authentic Severe Acute Respiratory Syndrome Coronavirus 2 Variants Carrying E484K In Vitro-Reference-Cited by-同舟云学术

Limited Neutralization of Authentic Severe Acute Respiratory Syndrome Coronavirus 2 Variants Carrying E484K In Vitro

Published:2021-06-05 Issue:7 Volume:224 Page:1109-1114
ISSN:0022-1899
Container-title:The Journal of Infectious Diseases
language:en
Short-container-title:

Author:

Widera Marek¹^ORCID,Wilhelm Alexander¹,Hoehl Sebastian¹^ORCID,Pallas Christiane¹,Kohmer Niko¹,Wolf Timo²³^ORCID,Rabenau Holger F¹,Corman Victor M⁴⁵,Drosten Christian⁴⁵,Vehreschild Maria J G T²³,Goetsch Udo⁶,Gottschalk Rene⁶,Ciesek Sandra¹⁵⁷

Affiliation:

1. Institute for Medical Virology, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt am Main, Germany

2. Department of Internal Medicine, Infectious Diseases, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt am Main, Germany

3. University Center for Infectious Diseases, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany

4. Institute of Virology, Charité-Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany

5. German Center for Infection Research, Braunschweig, Germany

6. Public Health Department of the City of Frankfurt am Main, Frankfurt am Main, Germany

7. Fraunhofer Institute for Molecular Biology and Applied Ecology, Branch Translational Medicine and Pharmacology, Frankfurt am Main, Germany

Abstract

Abstract Whether monoclonal antibodies are able to neutralize severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern has been investigated using pseudoviruses. In this study we show that bamlanivimab, casirivimab, and imdevimab efficiently neutralize authentic SARS-CoV-2, including variant B.1.1.7 (alpha), but variants B.1.351 (beta) and P.2 (zeta) were resistant against bamlanivimab and partially resistant to casirivimab. Whether antibodies are able to neutralize severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variantshas been investigated using pseudoviruses. We show that authentic SARS-CoV-2 carrying E484K were resistant against bamlanivimab and less susceptible to casirivimab, convalescent and vaccine-elicited sera.

Funder

Deutsche Forschungsgemeinschaft

Federal Ministry of Education and Research

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Immunology and Allergy

Link

http://academic.oup.com/jid/advance-article-pdf/doi/10.1093/infdis/jiab355/39589088/jiab355.pdf

Reference15 articles.

1. Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies;Greaney;Cell Host Microbe,2021

2. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19;Chen;N Engl J Med,2021